IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3950
Positioning
Market Dominance
Manufacturing
Medical Equipment
$2.0B
Reza Zadno
PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$PRCT PROCEPT BioRobotics Corp | 37 | 47 | 44 | 17 | - | - | -22.8% | -17.0% | 64.3% | -33.5% | -30.5% | 56.2% | 0.0% | 14.0x | $2.0B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
PROCEPT BioRobotics Corp (PRCT) receives a "Avoid" rating with a composite score of 36.6/100. It ranks #3950 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Fair valuation relative to peers
Average quality profile
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for PRCT.
View All RatingsROE proxy -22.8% (sector -1.9%)
GM 64% vs sector 44%, OM -33% vs sector 3%
Capital turnover N/A, R&D intensity 22.5%
Rev growth 56%, 5yr history
Interest coverage -25.2x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate PROCEPT BioRobotics Corp (PRCT) as Avoid with a composite score of 36.6/100 at a current price of $27.30. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
PROCEPT BioRobotics Corp holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 36.6/100 places it at rank #3950 in our full universe.
No Moat
Medium
Poor
Fair Value
Gross margins of 64% signal strong pricing power.
Stable competitive position in a defensive sector.
Weak momentum suggests persistent institutional selling pressure.
Vulnerability to macroeconomic shocks and interest rate volatility.
PROCEPT BioRobotics Corp represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags PROCEPT BioRobotics Corp with an Avoid rating, assigning a composite score of 36.6/100 and 1 out of 5 stars. Ranked #3950 of 7,333 stocks, PRCT falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
With a quality score of 47/100, PRCT shows adequate but unremarkable business quality. The company reports a return on equity of -22.8% (sector avg: -1.9%), gross margins of 64.3% (sector avg: 44.1%), net margins of -30.5% (sector avg: 1.0%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
With a value score of 44/100, PRCT appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 4.01x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
PROCEPT BioRobotics Corp's investment score of 29/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 56.2% vs. a sector average of 6.7% and a return on assets of -17.0% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
PROCEPT BioRobotics Corp is experiencing notably weak momentum with a score of just 17/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at 56.2% year-over-year, while a beta of 1.08 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
With a stability score of 58/100, PRCT exhibits average financial resilience. Key stability metrics include a beta of 1.08 and a debt-to-equity ratio of 14.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
PROCEPT BioRobotics Corp's short interest score of 25/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 14.00x), small-cap liquidity risk. At $2.0B (small-cap), PRCT carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
PROCEPT BioRobotics Corp is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3950 of 7,333 overall (46th percentile). Key comparisons include ROE of -22.8% trailing the -1.9% sector median and operating margins of -33.5% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While PRCT currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (17) would have the largest impact on the composite score.
ROE 1100% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 46% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 1434% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
SAN JOSE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that it has updated the timing of its previously announced fourth quarter 2025 earnings conference call and Investor Day due to significant travel disruptions caused by inclement weather. The Company will report financial results for the fourth quarter of
This article first appeared on GuruFocus. PROCEPT BioRobotics Corp (NASDAQ:PRCT) is set to release its Q4 2025 earnings on Feb 24, 2026. The consensus estimate for Q4 2025 revenue is $94.14 million, and the earnings are expected to come in at -$0.32 per share.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is one of the Overlooked Small Cap Stocks to Buy Now.
Procept BioRobotics reported strong Q2 2025 financial results with 48.3% revenue growth, reaching $79.2 million, driven by increased U.S. and international sales of robotic surgical systems for BPH treatment.
Preview Procept (PRCT) Q4 earnings on Feb 24 after close: consensus EPS -$0.32, revenue $93.7M; track record shows revenue beats.